[go: up one dir, main page]

SK4032003A3 - Association of the CB1 receptor antagonist and sibutramin, for treating obesity - Google Patents

Association of the CB1 receptor antagonist and sibutramin, for treating obesity Download PDF

Info

Publication number
SK4032003A3
SK4032003A3 SK403-2003A SK4032003A SK4032003A3 SK 4032003 A3 SK4032003 A3 SK 4032003A3 SK 4032003 A SK4032003 A SK 4032003A SK 4032003 A3 SK4032003 A3 SK 4032003A3
Authority
SK
Slovakia
Prior art keywords
methyl
chlorophenyl
bis
methylsulfonyl
azetidine
Prior art date
Application number
SK403-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Odile Piot-Grosjean
Philippe Picaut
Francois Petitet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8854974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK4032003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of SK4032003A3 publication Critical patent/SK4032003A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK403-2003A 2000-10-04 2001-10-01 Association of the CB1 receptor antagonist and sibutramin, for treating obesity SK4032003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012646A FR2814678B1 (fr) 2000-10-04 2000-10-04 Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
PCT/FR2001/003022 WO2002028346A2 (fr) 2000-10-04 2001-10-01 Association d'un antagoniste du recepteur cb1 et de sibutramine, pour le traitement de l'obesite

Publications (1)

Publication Number Publication Date
SK4032003A3 true SK4032003A3 (en) 2003-09-11

Family

ID=8854974

Family Applications (1)

Application Number Title Priority Date Filing Date
SK403-2003A SK4032003A3 (en) 2000-10-04 2001-10-01 Association of the CB1 receptor antagonist and sibutramin, for treating obesity

Country Status (29)

Country Link
EP (1) EP1328269B2 (xx)
JP (1) JP4221221B2 (xx)
KR (1) KR20030036885A (xx)
CN (1) CN100409845C (xx)
AT (1) ATE267595T1 (xx)
AU (2) AU2001293936B2 (xx)
BG (1) BG107739A (xx)
BR (1) BR0114410A (xx)
CA (1) CA2424934A1 (xx)
DE (1) DE60103556T3 (xx)
DK (1) DK1328269T5 (xx)
EA (1) EA005924B1 (xx)
EE (1) EE200300121A (xx)
ES (1) ES2217191T5 (xx)
FR (1) FR2814678B1 (xx)
HR (1) HRP20030249A2 (xx)
HU (1) HUP0302044A3 (xx)
IL (1) IL155236A0 (xx)
MX (1) MXPA03002845A (xx)
NO (1) NO20031521L (xx)
NZ (1) NZ524904A (xx)
PL (1) PL362833A1 (xx)
PT (1) PT1328269E (xx)
SI (1) SI1328269T2 (xx)
SK (1) SK4032003A3 (xx)
TR (1) TR200401264T4 (xx)
WO (1) WO2002028346A2 (xx)
YU (1) YU26103A (xx)
ZA (1) ZA200303015B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
JP2005531520A (ja) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド 置換２，３−ジフェニルピリジン類
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
CA2493313C (en) 2002-07-29 2010-03-09 F. Hoffmann-La Roche Ag Novel benzodioxoles
RU2339618C2 (ru) 2003-01-02 2008-11-27 Ф.Хоффманн-Ля Рош Аг Новые обратные агонисты рецептора св1
EP1583762B1 (en) 2003-01-02 2008-07-09 F. Hoffmann-La Roche Ag Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
RU2006100298A (ru) 2003-06-11 2006-05-10 Мерк энд Ко., Инк. (US) Замещенные производные 3-алкил-и 3-алкенилазетидинов
CN100368407C (zh) 2003-06-20 2008-02-13 霍夫曼-拉罗奇有限公司 作为cb1受体反激动剂的2-酰氨基苯并噻唑
EP1498122A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid systems containing azetidine derivatives
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2005049615A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
ATE384058T1 (de) 2003-12-08 2008-02-15 Hoffmann La Roche Thiazolderivate
ES2349195T3 (es) 2004-01-28 2010-12-28 F. Hoffmann-La Roche Ag Espiro-benzodioxoles y su uso como antagonistas de cb1.
CA2564986A1 (en) 2004-05-10 2005-11-17 F. Hoffmann-La Roche Ag Pyrrole or imidazole amides for treating obesity
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
FR2876689B1 (fr) * 2004-10-14 2008-02-22 Aventis Pharma Sa Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
WO2006045799A2 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
AU2005298986A1 (en) 2004-10-27 2006-05-04 F. Hoffmann-La Roche Ag New indole or benzimidazole derivatives
BRPI0517653A (pt) 2004-11-09 2008-10-14 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades e utilização dos compostos
PL1868999T3 (pl) 2005-04-06 2009-12-31 Hoffmann La Roche Pochodne pirydyno-3-karboksyamidu jako odwrotni agoniści CB1
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
JP2009528999A (ja) * 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド Ｃｂ１アンタゴニストおよび逆アゴニスト
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EA200900403A1 (ru) * 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
ES2439258T3 (es) * 2007-12-18 2014-01-22 Sanofi Derivados de azetidina, su preparación y su aplicación en terapia
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
BRPI0902481B8 (pt) 2009-07-31 2021-05-25 Soc Beneficente De Senhoras Hospital Sirio Libanes composição farmacêutica compreendendo hemopressina e seu uso.
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61928B1 (en) † 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
JPH04360167A (ja) * 1991-06-06 1992-12-14 Mitsubishi Kasei Corp 近接帯電装置
FR2713225B1 (fr) † 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
JPH07209959A (ja) * 1994-01-24 1995-08-11 Ricoh Co Ltd 帯電装置
US5596106A (en) † 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US6482927B1 (en) * 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
AU723879C (en) † 1996-10-31 2003-11-06 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
FR2758723B1 (fr) † 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6321134B1 (en) * 1997-07-29 2001-11-20 Silicon Genesis Corporation Clustertool system software using plasma immersion ion implantation
EP0920864A1 (en) † 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
IL141769A0 (en) † 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation

Also Published As

Publication number Publication date
JP2004512279A (ja) 2004-04-22
CN1473040A (zh) 2004-02-04
FR2814678B1 (fr) 2002-12-20
PT1328269E (pt) 2004-08-31
PL362833A1 (en) 2004-11-02
DE60103556T2 (de) 2005-06-30
DK1328269T3 (da) 2004-09-20
DE60103556D1 (de) 2004-07-01
EP1328269B2 (fr) 2008-07-30
BG107739A (bg) 2004-01-30
BR0114410A (pt) 2004-02-17
ZA200303015B (en) 2004-02-26
ES2217191T5 (es) 2009-02-16
DK1328269T5 (da) 2009-03-16
KR20030036885A (ko) 2003-05-09
EP1328269B1 (fr) 2004-05-26
NO20031521L (no) 2003-04-24
HRP20030249A2 (en) 2005-02-28
WO2002028346A2 (fr) 2002-04-11
DK1328269T4 (da) 2008-11-24
ATE267595T1 (de) 2004-06-15
MXPA03002845A (es) 2004-09-10
EE200300121A (et) 2005-04-15
WO2002028346A3 (fr) 2002-08-29
CA2424934A1 (fr) 2002-04-11
SI1328269T2 (sl) 2008-12-31
EP1328269A2 (fr) 2003-07-23
NO20031521D0 (no) 2003-04-03
SI1328269T1 (en) 2004-10-31
EA200300441A1 (ru) 2003-08-28
ES2217191T3 (es) 2004-11-01
AU2001293936B2 (en) 2007-01-25
DE60103556T3 (de) 2009-04-09
TR200401264T4 (tr) 2004-07-21
IL155236A0 (en) 2003-11-23
NZ524904A (en) 2004-11-26
FR2814678A1 (fr) 2002-04-05
EA005924B1 (ru) 2005-08-25
HUP0302044A3 (en) 2005-05-30
AU9393601A (en) 2002-04-15
HUP0302044A2 (hu) 2003-11-28
JP4221221B2 (ja) 2009-02-12
CN100409845C (zh) 2008-08-13
YU26103A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
SK4032003A3 (en) Association of the CB1 receptor antagonist and sibutramin, for treating obesity
US7037944B2 (en) Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
JP2005505539A5 (xx)
RU2001110080A (ru) Производные азетидина, способ их получения и содержащие их лекарственные препараты
RU2008127491A (ru) Применение антагониста cb1 для лечения побочных эффектов и негативных симптомов шизофрении
JP2003522145A (ja) セントラルカンナビノイドレセプター拮抗剤のタバコ消費を止める助けに有用である医薬品への使用
JP2001501971A (ja) 中枢性カンナビノイドレセプターアンタゴニストの欲求（ａｐｐｅｔｅｎｃｅ）を制御するための使用
RU2002119016A (ru) N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]карбоксамидные ингибиторы циклин-зависимых киназ
JP2004509857A5 (xx)
JP2005505539A (ja) パーキンソン病の治療のためのｃｂ１受容体アンタゴニストと、脳のドーパミン作用性神経伝達を活性化する製品を含む組成物
RU2006123418A (ru) Новые антагонисты м3 мускаринового ацетилхолинового рецептора
RU2019111886A (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
JP2009525993A (ja) 統合失調症の症状を治療または軽減するためにｋｃｎｑ開口薬を使用する方法
JPH07196502A (ja) 閉経期後の女性におけるｃｎｓ障害を抑制するための医薬組成物
RU2007127864A (ru) Производные n-[(4, 5-дифенил-3-алкил-2-тиенил)метил]амина (амид, сульфонамид, карбамат и карбамид) в качестве антагонистов рецепторов св1 каннабиноидов
RU2003131971A (ru) Производные 4-(фенил-пиперидин-4-илиден-метил)-бензамида и их применение для лечения боли, тревоги или желудочно-кишечных расстройств
RU2003115431A (ru) Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина
SK161197A3 (en) Use of pyrrolidine derivatives for treating alcoholism
JP2013035873A (ja) 神経障害の治療における選択的オピエート受容体調節物質の使用
WO2021029434A1 (ja) 首下がり症候群および胸腰椎脊柱変形の治療薬
US20030212109A1 (en) Pharmaceutical compositions and their use
RU2585378C1 (ru) Твердая дозированная лекарственная форма для орального введения, содержащая комбинацию вилдаглиптина и гликвидона
JP2006502095A5 (xx)
CN105873611A (zh) 利用pde4调节剂治疗病毒性疾病的组合物和方法

Legal Events

Date Code Title Description
FC9A Refused patent application